Apogee Therapeutics entered into a definitive merger agreement to be acquired by AbbVie in an all-cash transaction valued at approximately $10.9 billion, offering $135.11 per share. Additionally, the company reported positive Phase 2 clinical trial results for its lead immunology candidate zumilokibart, positioning the portfolio for continued advancement toward regulatory milestones.